Prognosis evaluation of ameloblastoma—A study based on SEER database
Jin Yi1,2, Yang Pei1, Jin Hekun1, Han Yaqian1, Wu Xiangwei1, Wang Hui1,2
1Department of Radiation Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; 2Key Laboratory of Translational Radiation Oncology, Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China
Abstract：Objective Ameloblastoma (AM) is a rare tumor derived from dental epithelial tissues, which is prone to recurrence and infiltration. This study aims to identify the prognostic factors of AM. Methods 207 ameloblastoma patients were screened from the SEER database. A Cox regression model and nomogram were constructed to evaluate the factors on the overall survival. Clinical data of 61 patients admitted to Hunan Cancer Hospital were retrospectively analyzed. The independent factors of recurrence rate were analyzed by the Cox regression model. Results The results on the SEER database showed that age, tumor size, type of surgery, radiotherapy were important prognostic factors of the overall survival. The nomogram was constructed and the C-index was equaled to 0.821, indicating this model was moderately accurate. The receiver operating characteristic (ROC) curve demonstrated that the area under the ROC curve (AUC) at 1, 3, 5, and 10 years were 0.852, 0.869, 0.856, and 0.879, indicating this model had relatively high sensitivity and specificity. Kaplan-Meier survival analysis suggested that overall survival in the high-risk group was significantly lower than that in the low-risk group (P<0.001). Based on retrospective analysis, clinical symptoms and type of surgery were the independent factors of the local recurrence rate. Kaplan-Meier survival analysis found the recurrence rate of facial swelling and pain was lower compared to those of other symptoms. Compared with the palliative surgery, radical surgery could decrease the recurrence rate. Conclusions Age, tumor size, type of surgery, and radiotherapy may be important factors of the overall survival. Type of surgery and clinical symptoms are probably the independent factors of the recurrence rate.
Jin Yi,Yang Pei,Jin Hekun et al. Prognosis evaluation of ameloblastoma—A study based on SEER database[J]. Chinese Journal of Radiation Oncology, 2021, 30(7): 659-664.
[1] Almeida Rde A, Andrade ES, Barbalho JC, et al. Recurrence rate following treatment for primary multicystic ameloblastoma:systematic review and meta-analysis[J]. Int J Oral Maxillofac Surg, 2016, 45(3):359-367. DOI:10.1016/j.ijom.2015.12.016. [2] Agbaje JO, Olumuyiwa Adisa A, Ivanova Petrova M, et al. Biological profile of ameloblastoma and its location in the jaw in 1246 Nigerians[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2018, 126(5):424-431. DOI:10.1016/j.oooo.2018.06.014. [3] Milman T, Ying GS, Pan W, et al. Ameloblastoma:25 year experience at a single institution[J]. Head Neck Pathol, 2016, 10(4):513-520. DOI:10.1007/s12105-016-0734-5. [4] Abe M, Zong L, Abe T, et al. A turning point in therapy for ameloblastomas[J]. Oral Oncol, 2018, 80:95-96. DOI:10.1016/j.oraloncology.2018.03.007. [5] McClary AC, West RB, McClary AC, et al. Ameloblastoma:a clinical review and trends in management[J]. Eur Arch Otorhinolaryngol, 2016, 273(7):1649-1661. DOI:10.1007/s00405-015-3631-8. [6] Simpson MC, Massa ST, Boakye EA, et al. Primary cancer vs. competing causes of death in survivors of head and neck cancer[J]. JAMA Oncol, 2018, 4(2):257-259. DOI:10.1001/jamaoncol.2017.4478. [7] Brown NA, Betz BL. Ameloblastoma:a review of recent molecular pathogenetic discoveries[J]. Biomark Cancer, 2015, 7(Suppl 2):19-24. DOI:10.4137/BIC. S29329. [8] Jussila M, Thesleff I. Signaling networks regulating tooth organogenesis and regeneration, and the specification of dental mesenchymal and epithelial cell lineages[J]. Cold Spring Harb Perspect Biol, 2012, 4(4):a008425. DOI:10.1101/cshperspect.a008425. [9] Alves D, Tuji FM, Alves FA, et al. Evaluation of mandibular odontogenic keratocyst and ameloblastoma by panoramic radiograph and computed tomography[J]. Dentomaxillofac Radiol, 2018, 47(7):20170288. DOI:10.1259/dmfr.20170288. [10] Pappalardo M, Tsao CK, Tsang ml, et al. Long-term outcome of patients with or without osseointegrated implants after resection of mandibular ameloblastoma and reconstruction with vascularized bone graft:functional assessment and quality of life[J]. J Plast Reconstr Aesthet Surg, 2018, 71(7):1076-1085. DOI:10.1016/j.bjps.2018.03.008. [11] Satagopan JM, Ben-Porat L, Berwick M, et al. A note on competing risks in survival data analysis[J]. Br J Cancer, 2004, 91(7):1229-1235. DOI:10.1038/sj.bjc.6602102. [12] Au SW, Li KY, Choi WS, et al. Risk factors for recurrence of ameloblastoma:a long-term follow-up retrospective study[J]. Int J Oral Maxillofac Surg, 2019, 48(10):1300-1306. DOI:10.1016/j.ijom.2019.04.008. [13] Sehdev MK, Huvos AG, Strong EW, et al. Proceedings:ameloblastoma of maxilla and mandible[J]. Cancer,1974,33(2):324-333. DOI:10.1002/1097-0142(197402)33:2<324::aid-cncr2820330205>3.0.co;2-u. [14] Shatkin S, Hoffmeister FS. Ameloblastoma:a rational approach to therapy[J]. Oral Surg Oral Med Oral Pathol, 1965, 20(4):421-435. DOI:10.1016/0030-4220(65)90231-8. [15] Mehlisch DR, Dahlin DC, Masson JK. Ameloblastoma:a clinicopathologic report[J]. J Oral Surg, 1972, 30(1):9-22. [16] Nakamura N, Higuchi Y, Mitsuyasu T, et al. Comparison of long-term results between different approaches to ameloblastoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2002, 93(1):13-20. DOI:10.1067/moe.2002.119517. [17] Dissanayake RK, Jayasooriya PR, Siriwardena DJ, et al. Review of metastasizing (malignant) ameloblastoma (METAM):pattern of metastasis and treatment[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011, 111(6):734-741. DOI:10.1016/j.tripleo.2010.12.018. [18] Gardner DG. Radiotherapy in the treatment of ameloblastoma[J]. Int J Oral Maxillofac Surg, 1988, 17(3):201-205. DOI:10.1016/s0901-5027(88)80033-x. [19] Miyamoto CT, Brady LW, Markoe A, et al. Ameloblastoma of the jaw. Treatment with radiation therapy and a case report[J]. Am J Clin Oncol, 1991, 14(3):225-230. [20] Kennedy WR, Werning JW, Kaye FJ, et al. Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy[J].Eur Arch Otorhinolaryngol, 2016, 273(10):3293-3297. DOI:10.1007/s00405-016-3899-3. [21] Petrovic ID, Migliacci J, Ganly I, et al. Ameloblastomas of the mandible and maxilla[J]. Ear Nose Throat J, 2018, 97(7):E26-E32. DOI:10.1177/014556131809700704. [22] Amzerin M, Fadoukhair Z, Belbaraka R, et al. Metastatic ameloblastoma responding to combination chemotherapy:case report and review of the literature[J]. J Med Case Rep, 2011, 5:491. DOI:10.1186/1752-1947-5-491. [23] Yang RN, Wang XS, Ren J, et al. Mandible ameloblastoma with lung metastasis:a rare case report[J]. Int J Clin Exp Pathol, 2015, 8(6):6793-6799.
2021, Vol. 30 
